Please login to the form below

Not currently logged in
Email:
Password:

Tracleer

This page shows the latest Tracleer news and features for those working in and with pharma, biotech and healthcare.

FDA ‘names and shames’ generic-blocking pharma companies

FDA ‘names and shames’ generic-blocking pharma companies

Pomalyst, followed by Actelion with 26 inquiries mainly for pulmonary artery hypertension drugs Tracleer and Opsumit.

Latest news

More from news
Approximately 7 fully matching, plus 32 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... Under his leadership Tracleer was built into a global brand with almost

  • New associate director at Packer Forbes New associate director at Packer Forbes

    Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • New Senior Appointment

    diabetes. She began her career in healthcare as a pharmaceutical marketeer with Merck-Serono and then joined Actelion UK as Brand Lead for its first-in-class pulmonary hypertension treatment, Tracleer.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics